ArticleScientific reports2025
Ferroptosis and autophagy-related genes contribute to hypertrophic cardiomyopathy progression.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
We aimed to investigate the ferroptosis- and autophagy-related differentially expressed genes (DEGs) that might be potential targets for hypertrophic cardiomyopathy (HCM) progression.GSE89714 and ferroptosis- and autophagy databases were utilized to obtain the overlapping ferroptosis- and autophagy-related DEGs. Enrichment pathway analysis was performed and the hub genes were obtained. The HCM mice model, macrophage cell Line and single-cell sequencing data were used to validate the hub genes. Utilizing the Limma package and Venn diagram, 25 ferroptosis-related and 47 autophagy-related DEGs were obtained. They were mainly enriched in autophagy, ferroptosis, neurodegeneration pathways, multiple diseases, processes utilizing autophagic mechanisms, hijacked molecular function, and antioxidant activity. In the protein-protein interaction network, the hub DEGs, including BCL2L1, CD44, IGF1, CDKN1B, APP, CTNNB1, HMGB1, LAMP1, TFRC, and CXCR4 were obtained. Using a single-cell portal, sequencing of hub gene expression demonstrated that the hub genes were highly expressed in macrophages in the human and HCM hearts. The screened hub genes, BCL2L1, CD44, IGF1, CDKN1B, APP, CTNNB1, HMGB1, LAMP1, TFRC, and CXCR4, may be therapeutic targets for diagnosing HCM and its progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.